BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11932275)

  • 1. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
    Fatourechi V; Hay ID; Javedan H; Wiseman GA; Mullan BP; Gorman CA
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1521-6. PubMed ID: 11932275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
    Tepmongkol S; Keelawat S; Honsawek S; Ruangvejvorachai P
    Thyroid; 2008 Jul; 18(7):697-704. PubMed ID: 18630997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
    Fatourechi V; Hay ID
    Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
    Bachelot A; Leboulleux S; Baudin E; Hartl DM; Caillou B; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):376-9. PubMed ID: 15730423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
    Pineda JD; Lee T; Ain K; Reynolds JC; Robbins J
    J Clin Endocrinol Metab; 1995 May; 80(5):1488-92. PubMed ID: 7744991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
    Pacini F; Agate L; Elisei R; Capezzone M; Ceccarelli C; Lippi F; Molinaro E; Pinchera A
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4092-7. PubMed ID: 11549631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
    Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
    J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
    Westbury C; Vini L; Fisher C; Harmer C
    Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid.
    Besic N; Vidergar-Kralj B; Frkovic-Grazio S; Movrin-Stanovnik T; Auersperg M
    Thyroid; 2003 Jun; 13(6):577-84. PubMed ID: 12930602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.